Detemir: Role in Type 1 Diabetes

Montefiore Medical Center18 enrolled

Overview

Study of blood sugars in the children with Type 1 Diabetes Mellitus (T1DM), who are given insulin detemir and a rapid acting insulin (aspart). It is hypothesized that there is no difference in the patterns of blood sugars when detemir is given in the same syringe or in separate syringes with rapid acting insulin.

One of the barriers to good glycemic control in children with type 1 diabetes is multiple daily insulin injections. Mixing rapid-acting (detemir) and slow- acting insulins (aspart) in the same syringe would decrease the number of injections and may improve adherence This study hypothesized that slow-acting insulin detemir mixed with aspart would have equivalent effects on blood glucose versus giving them as separate injections in children with type 1 diabetes. Eighteen pediatric subjects with type 1 diabetes (11 males and 7 females) were recruited. However only 14 subjects completed this 20-day, randomized, crossover, and open-labeled study. The subjects were randomly assigned to either Study A (both insulin detemir and rapid acting insulin (RAI)) or Study B (either detemir or aspart) for the first 10 days. They were then crossed over for the last 10 days. Each subject underwent 72 h of continuous glucose monitoring (CGM) during the last 72 h, for both Study A and Study B.Data of 48 h from midnight of the 1st day to mid- night of the 3rd day of the 72-h (CGM) were used for analysis to ensure the same starting and ending times of monitoring for all subjects.Sustained glucose values over time were calculated as area under the curve (AUC), index of blood glucose control as M-value and glucose excursion as mean amplitude of glucose excursion (MAGE)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Type 1 Diabetes Mellitus

Interventions

Insulin Detemir mixed with RAI injectionDRUG

Insulin Detemir mixed with RAI injection is given twice daily as subcutaneous injection

Insulin Detemir and RAI injectionDRUG

Insulin detemir and RAI are given as separate injections, twice daily as subcutaneous injection

Eligibility

Sex: ALLMin age: 10 YearsMax age: 25 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with antibody positive Type 1 Diabetes Mellitus (T1DM) * On insulin glargine for at least 3 months * Age 10-25 years * Not on medications that may affect glucose concentrations * Hemoglobin A1C (HbA1C) of less than 9 % * Body Mass Index (BMI) less than 95th % and more than 10th% * Supportive family Exclusion Criteria: * Subjects with undetermined diabetes or Type 2 Diabetes Mellitus (T2DM) * Unable to adhere to insulin regimen * Positive urine pregnancy test

Locations (1)

Texas Children's Hospital Endocrine and Diabetes Clinic

Houston, Texas, United States

Outcomes

Primary Outcomes

Assess the Mean Area Under the Curve (AUC) for Blood Glucose Concentration in Subjects Treated With Either Insulin Detemir Mixed With Rapid Acting Insulin (RAI) or Insulin Detemir and RAI as Separate Subcutaneous Injections

Blood glucose concentration in terms of mean AUC (0-48 hours)was determined in subjects treated with either Insulin Detemir mixed with RAI or Insulin Detemir and RAI as separate subcutaneous injections.

Time frame: 0-48 hours post-dose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.